<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To explore the significance of nonmyeloablative allogeneic peripheral blood hematopoietic stem cell transplantation in the treatment of <z:e sem="disease" ids="C0018939" disease_type="Disease or Syndrome" abbrv="">hematological diseases</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: A nonmyeloablative conditioning regimen consisted of CD(3) monoclonal antibody, <z:chebi fb="0" ids="4031">cyclosporine</z:chebi> A, <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> and <z:chebi fb="0" ids="28680">cytarabine</z:chebi> was used for allogeneic stem cell transplantation in 33 patients with <z:e sem="disease" ids="C0018939" disease_type="Disease or Syndrome" abbrv="">hematological diseases</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Of them, 11 were <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> (AL) in first complete remission (CR(1)), 4 AL-CR(2) approximately 3, 3 refractory AL, 4 severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> (SAA), 7 <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:mp ids='MP_0005481'>CML</z:mp>), 2 <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo>, 1 each of <z:hpo ids='HP_0005550'>chronic lymphocytic leukemia</z:hpo> (CLL) and <z:hpo ids='HP_0011974'>myelofibrosis</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: <z:hpo ids='HP_0000001'>All</z:hpo> 33 patients passed the hematopoietic suppression stage smoothly and achieved engraftment of the donor cells </plain></SENT>
<SENT sid="4" pm="."><plain>There were 24 cases of full donor chimerism (13 cases converted from mixed chimerism), 4 mixed chimerism (MC) and 5 developed graft rejection </plain></SENT>
<SENT sid="5" pm="."><plain>Of the 33 cases, 7 (21.2%) developed <z:hpo ids='HP_0011009'>acute</z:hpo> GVHD and <z:hpo ids='HP_0011010'>chronic</z:hpo> GVHD, 25 (75.8%) still live and 8 (24.2%) died </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSIONS: Nonmyeloablative allogeneic peripheral blood stem cells transplantation is a safe, less toxic and curative approach for patients with <z:e sem="disease" ids="C0018939" disease_type="Disease or Syndrome" abbrv="">hematological disease</z:e> </plain></SENT>
</text></document>